About your Search

Search Results 0 to 3 of about 4
be thriving in an environment where lots of people are worried about their taxes going up year end and the fiscal cliff is starting to get top of mind. you have a stock like walmart which has been a juggernaut, going up in a straight line since april until the recent pullback. then there is a company like -- sell, sell, sell. jcpenney. if you thought things couldn't get worse for jcpenney under the ceo, well, you were very wrong. as the company missed estimates once again on friday, reporting absolutely hideous numbers, they were blinding. sure enough, penney's continued the decline today, down another $2.67, 13%. like the wheel of fortune, where she stops, nobody knows. far more important, just so you know, there is a piece of preferred, there is another corporate piece of paper affiliated with jcpenney and that is sinking like a stone. that is more valuable to tell how bad things at jcpenney are. johnson tried to revolutionize by getting rid of coupons, cutting price as cross the board, they failed tragically and they started issuing coupons again. customers don't trust them. jc
it is not a major league stock. it is the wrong stock for this environment. >> susan. >> how do you feel about exel? >> i like exel. and by the way, another one of -- another one of our specs, dbax, nice move today. remember, i am in favor of speculation as long as it's only one small piece of your portfolio. and that is the conclusion of the lightning round. a febreze experiment. can a 30-day-old pluggable febreze make even this old container smell fresh? take a deep breath. describe the room that you're in. i think just like a big, open space. like i'm hanging the sheets on the line. and it smells really fresh, man. let's take your blindfold off. oh! [ both laugh ] super-weird! oh, is it febreze? yeah. ohh, how about that? febreze has anti-clogging technology that keeps it smelling fresh, even after 30 days. febreze. breathe happy. i have a cold, and i took nyquil, but i'm still "stubbed" up. [ male announcer ] truth is, nyquil doesn't unstuff your nose. what? [ male announcer ] it doesn't have a decongestant. no way. [ male announcer ] sorry. alka-seltzer plus fights your worst cold symptoms plu
ones. i am searching for the companies that i like that can thrive in this environment with the fiscal cliff and with a recession a possibility. look, it's a possibility if they don't solve this thing. today i was throwing a surprise party for amgen. you know what, fiscal cliff, no fiscal cliff, we're still having an amgen party here. inappropriate balloon moment there. they make all kinds of drugs for many serious illnesses. it has seven products in development that are starting phase three clinical trials in the early part of next year. phase three means it's getting near fruition. amgen could double earnings per share over the next eight years. that is much better than a sharp stick in the retina. amgen reported on october 23rd after the close and the company delivered spectacular results and was a true triple play. earnings came in $1.67, and revenues 5.9% year over year. when the street was looking for $4.25 billion. management's four-year guidance, substantially higher than the analysts expecting. those were fabulous numbers. no surprise that the stock shot up from $87.32, to nea
Search Results 0 to 3 of about 4